Expert review of hematology · 2025
PRDX6 knockdown sensitizes multiple myeloma cells to ferroptosis through inactivation of the PI3K/AKT pathway.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Guifang, Zhang Hongju, Wang Yun, Lu Jingfeng, Dong Ke, Gao Wu
Аннотация
BACKGROUND: This study probes into the impact and mechanisms of PRDX6 on ferroptosis multiple myeloma (MM).
RESEARCH DESIGN AND METHODS: PRDX6 expression in MM cells were determined using Western blotting and qRT-PCR. MM cells were treated with pLKO-shPRDX6 vectors expressing PRDX6 shRNA alone or in combination with Erastin/ferrostatin-1 (ferroptosis activator/inhibitor) or 740Y-P (PI3K/AKT pathway activator). Cell viability, apoptosis, Fe2+ concentration, and ROS levels were examined using CCK-8, flow cytometric analysis, iron ion detection, and DCFH-DA assay, and ELISA. Malondialdehyde (MDA) and glutathione (GSH) levels were tested with ELISA, and SLC7A11 and GPX4 levels were measured with Western blotting.
RESULTS: PRDX6 expression was sharply increased in MM cells (p < 0.01). Silencing of PRDX6 sensitized MM cells to ferroptosis, as indicated by elevated Fe2+, ROS, and MDA levels but decreased GSH, SLC7A11, and GPX4 levels (p < 0.05), and these trends were neutralized by 740Y-P treatment. Furthermore, PRDX6 knockdown lowered the levels of PI3K/AKT pathway-associated molecules (p < 0.05).
CONCLUSIONS: PRDX6 knockdown may exert pro-ferroptotic effects through inactivation of the PI3K/AKT pathway, underlying an appealing therapeutic target for MM.
RESEARCH DESIGN AND METHODS: PRDX6 expression in MM cells were determined using Western blotting and qRT-PCR. MM cells were treated with pLKO-shPRDX6 vectors expressing PRDX6 shRNA alone or in combination with Erastin/ferrostatin-1 (ferroptosis activator/inhibitor) or 740Y-P (PI3K/AKT pathway activator). Cell viability, apoptosis, Fe2+ concentration, and ROS levels were examined using CCK-8, flow cytometric analysis, iron ion detection, and DCFH-DA assay, and ELISA. Malondialdehyde (MDA) and glutathione (GSH) levels were tested with ELISA, and SLC7A11 and GPX4 levels were measured with Western blotting.
RESULTS: PRDX6 expression was sharply increased in MM cells (p < 0.01). Silencing of PRDX6 sensitized MM cells to ferroptosis, as indicated by elevated Fe2+, ROS, and MDA levels but decreased GSH, SLC7A11, and GPX4 levels (p < 0.05), and these trends were neutralized by 740Y-P treatment. Furthermore, PRDX6 knockdown lowered the levels of PI3K/AKT pathway-associated molecules (p < 0.05).
CONCLUSIONS: PRDX6 knockdown may exert pro-ferroptotic effects through inactivation of the PI3K/AKT pathway, underlying an appealing therapeutic target for MM.